Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disease that affects the central nervous system, leading to a range of symptoms including fatigue, difficulty walking, numbness, and vision problems. It can occur in both adults and children.
Multiple Sclerosis in Kids: Ofatumumab and Siponimod Study
We are comparing two new treatments, ofatumumab and siponimod, to fingolimod in children with multiple sclerosis. The study aims to see if these new options are as effective and safe for managing their condition.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 10 and 17 years old?
- Do you have a diagnosis of multiple sclerosis (MS)?
- Are you currently pregnant or breastfeeding?
- Do you have any severe infections, like tuberculosis, that are active right now?
- Have you been diagnosed with any other significant health condition that might prevent you from participating?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Baf312
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Vienna
1011 : Deaprtment Neurology
Vienna, Austria
Universitair Ziekenhuis Gent
1140 : Pediatry
Ledeberg, Belgium
Centre hospitalier universitaire de Liege
1141 : Neurology
Tilff, Belgium
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.